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Abstract
While the morphological and electrophysiological changes underlying diabetic peripheral neuropathy (DPN) are relatively
well described, the involved molecular mechanisms remain poorly understood. In this study, we investigated whether
phenotypic changes associated with early DPN are correlated with transcriptional alterations in the neuronal (dorsal root
ganglia [DRG]) or the glial (endoneurium) compartments of the peripheral nerve. We used Ins2Akita/+ mice to study
transcriptional changes underlying the onset of DPN in type 1 diabetes mellitus (DM). Weight, blood glucose and motor
nerve conduction velocity (MNCV) were measured in Ins2Akita/+ and control mice during the first three months of life in order
to determine the onset of DPN. Based on this phenotypic characterization, we performed gene expression profiling using
sciatic nerve endoneurium and DRG isolated from pre-symptomatic and early symptomatic Ins2Akita/+ mice and sex-matched
littermate controls. Our phenotypic analysis of Ins2Akita/+ mice revealed that DPN, as measured by reduced MNCV, is
detectable in affected animals already one week after the onset of hyperglycemia. Surprisingly, the onset of DPN was not
associated with any major persistent changes in gene expression profiles in either sciatic nerve endoneurium or DRG. Our
data thus demonstrated that the transcriptional programs in both endoneurial and neuronal compartments of the
peripheral nerve are relatively resistant to the onset of hyperglycemia and hypoinsulinemia suggesting that either minor
transcriptional alterations or changes on the proteomic level are responsible for the functional deficits associated with the
onset of DPN in type 1 DM.
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Introduction
Diabetic peripheral neuropathy (DPN) is the most common
complication of diabetes mellitus (DM) [1]. Up to half of all
individuals with DM develop DPN with a lifetime risk of lower
extremity amputations estimated at 15% [2]. Typically, symptoms
begin in the feet and progress to proximal regions, finally affecting
the upper limbs, the abdomen and the thorax [3]. Diabetic
patients may experience impaired tactile, thermal and pain
sensations with dysautonomic manifestations such as sexual
dysfunction, gastrointestinal abnormalities and cardiac arrhythmi-
as. On the other hand, some patients also experience neural
hyperexcitability inducing tingling, itching, burning, cramps and
neuropathic pain [4,5,6]. A decrease in nerve conduction velocity
(NCV) is the most consistent electrophysiological marker of DPN
[4,6]. Progression of DPN can be divided into 2 main phases [7].
The early stage of DPN is characterized by reversible deficits such
as decreased NCV, decreased endoneurial blood flow, impairment
of Na+/K+-ATPase and nitric oxide activities. Using animal
models of type 1 DM (streptozotocin (STZ)-injected rats), it has
been shown that these early defects cannot be attributed to nerve
structural abnormalities [8]. At the later stage, other pathogenic
components are progressively added, inducing structural changes
such as segmental demyelination, axo-glial dysjunction and axonal
atrophy. These structural modifications are irreversible [7].
Even though the above-mentioned pathological alterations
affecting neuronal structures are relatively well described,
molecular mechanisms underlying DPN remain poorly under-
stood. Several interrelated metabolic abnormalities resulting from
hyperglycemia, insulin and C-peptide deficiencies may be
involved. So far, proposed mechanisms include altered metabolism
of glucose via the polyol pathway, advanced glycation end
products, increased protein kinase C (PKC) activity, altered
neurotropism, perturbation of lipid metabolism, ischemia and
reactive oxygen species [4,6,9,10]. Currently, also the identity of
the cell type first to be affected in DPN is unclear, as defects are
observed in basically all cell types composing the nerve. Some
authors claimed that DPN is primarily an axonal pathology
[11,12], whereas others support the hypothesis that DPN is a
Schwann cell-related disorder [7,13].
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The search for changes in expression levels of candidate genes
underlying DPN pathological hallmarks has been attempted
previously, in either sciatic nerve or DRG compartments of the
PNS [14–22]. These studies were complemented by more global
transcriptomic approaches in either sympathetic ganglia [23],
DRG [24] or in immortalized adult mouse Schwann cells [25].
However, the comparison of the effects of hyperglycemia on the
stability of transcriptional programs in vivo, between the neuronal
(DRG) and glial compartments of the peripheral nerve, was never
attempted.
To address this question, we used Ins2Akita/+ mice as a model of
type 1 DM related DPN, and we concentrated on the early stages
of DPN development when the pathological changes affecting
neuronal function are still reversible. To define the progression of
DPN in this model, we performed a detailed phenotypic
characterization of Ins2Akita/+ mice. NCV changes could be
detected quite rapidly in this type 1 DM model, only one week
after the onset of hyperglycemia. Based on these phenotypic data,
we performed a gene expression profile of the sciatic nerve
endoneurium (mostly containing Schwann cells) and DRG (mostly
containing somas of sensory neurons) isolated from pre-symptom-
atic and early symptomatic Ins2Akita/+ mice. We observed that both
neuronal and glial transcriptomes are stable during early stages of
diabetes. These data therefore suggest that the functional deficits
associated with the onset of DPN are rather a consequence of a
combination of minor transcriptional alterations and/or changes
on the proteomic level.
Results
Phenotypic characterization of the development of DPN
in Ins2Akita/+ mice
We have selected Ins2Akita/+ mice as a model of type 1 DPN. In
this mouse model, diabetes is a consequence of an autosomal
dominant mutation in the Ins2 gene resulting in the improper
folding of the Proinsulin 2 protein leading to hypoinsulinemia and
hyperglycemia [26]. Ins2Akita/+ mice develop multiple secondary
complications associated with diabetes including neuropathy [27]
and retinopathy [28].
In order to select time-points for transcriptional analysis that are
matching the onset of neuropathy in Ins2Akita/+ mice, we first
characterized the development of DPN in this model. Weight, tail
vein blood glucose and motor nerve conduction velocity (MNCV)
were followed in four male Ins2Akita/+ and four control littermates
between three and ten weeks of age. No significant variation of
weight was observed between Ins2Akita/+ mice and their control
littermates (Fig. 1A). Blood glucose level started to increase in
Ins2Akita/+ between three to four weeks of age (Fig. 1B) and
reached a plateau approximately five weeks after the onset of
hyperglycemia. In order to match the onset of hyperglycemia with
the onset of DPN, we measured MNCV in Ins2Akita/+ mice and
control littermates. Reduced NCV is an established early marker
of DPN in patients [6]. At three and four weeks of age, no
difference in MNCV was detected between Ins2Akita/+ mice and
control littermates. At five weeks of age, about one week after the
onset of hyperglycemia, a decrease in MNCV was clearly present
in Ins2Akita/+ mice and this condition was maintained (but it did not
worsen) as mice aged (Fig. 1C). In order to determine if the
observed decrease in MNCV was also reproduced in sensory
fibers, tail sensory NCV (SNCV) and MNCV were measured in
two and five month old animals. SNCV could not be determined
in younger mice, the tail being too small to allow reproducible
results. In control animals, measured SNCV were lower than that
of motor fibers, however the obtained values were in the range of
the previously published results [27]. Similar to MNCV, the tail
SNCV was decreased in Ins2Akita/+ mice as compared to control
littermates at two and five months of age, suggesting that both
sensory and motor NCV are affected in this model of DPN
(Fig. 2A and B). We have also observed a similar tendency for a
decrease in SNCV at the level of the sciatic nerve (Fig. S1).
Sensory symptoms observed in DPN patients often include both
loss of sensations and neuropathic pain [4,29]. To evaluate
Ins2Akita/+ mice sensory behavior, the development of a thermal
hypo- or hyper-sensitivity was assessed in two month old animals
using a hotplate. In this test, Ins2Akita/+ mice showed a significantly
slower reaction time to heat at 49uC (p=0.002) and 52uC
(p=0.005) (Fig. 2C). In contrast, no difference was observed at
55uC. These sensory symptoms were not associated with changes
in intraepidermal nerve fiber density which is a marker of small
fiber damage in more advanced human DPN (Fig. S2, [30]).
The Ins2Akita/+ animals presented a reduction of MNCV at five
weeks of age. At this time-point, the peripheral nerves are still
maturing as demonstrated by an increase in MNCV in wild-type
animals between the ages of 5 and 10 weeks (Fig. 1C). In order to
eliminate the possibility that the decreased MNCV present in
Ins2Akita/+ animals is a consequence of slowed PNS maturation
leading to either hypomyelination and/or change in radial axonal
growth (insulin signaling is known to affect Schwann cell and
neuronal development [4,5,6]), we evaluated the level of
myelination and axonal size distribution in three month old
Figure 1. Phenotypic characterization of Ins2Akita/+ mice. Body weight (A), tail vein blood glucose (B) and motor nerve conduction velocity
(MNCV, C) were measured at depicted time-points in Ins2Akita/+ and Ins2+/+ mice. All results are expressed as the mean 6 standard error of the mean
(S.E.M.). (Ins2+/+: n = 4; Ins2Akita/+: n = 4).
doi:10.1371/journal.pone.0010832.g001
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control and Ins2Akita/+ animals. While at this developmental stage
Ins2Akita/+ animals presented decreased MNCV, SNCV and slower
reaction time to heat (Fig. 2), we could not detect any structural
changes in their PNS (Fig. 3A–C). Together our data therefore
suggest that the DPN phenotypes observed in Ins2Akita/+ animals
during the early phase of the disease (the first two months after the
onset) are a consequence of the effect of the diabetic condition on
their PNS function and not on the structure.
Analysis of the effect of the onset of diabetes on
endoneurial and neuronal transcriptomes
To detect the primary transcriptional changes associated with
the development of DPN in Ins2Akita/+ mice, gene expression
profiling of the DRG and of the sciatic nerve endoneurium were
carried out. Based on phenotypical characterization described
above, eight time-points (postnatal days P20, P24, P28, P32, P36,
P40, P48 and P56) covering the early stages of the neuropathy
were selected (Fig. 4A). Until P24 (P20 and P24), Ins2Akita/+ mice
did not show any pathological phenotype (hyperglycemia or
neuropathy). Starting from P28, glycemia was increased in affected
mice and DPN was clearly detectable at P36, approximately one
week after the onset of hyperglycemia. While hyperglycemia
increased in Ins2Akita/+ mice between P36 and P56, symptoms of
DPN did not progressively worsen over time.
‘‘Present’’, ‘‘marginal’’ and ‘‘absent’’ calls were used for the first
step of microarray data filtering (Fig. 4B). Since very closely
spaced time-points were used, we considered all genes called
‘‘present’’ only at one developmental stage as artifacts and
eliminated them from further analysis. Thus only probes called
‘‘present’’ in at least 2 consecutive time-points were selected
leading to the elimination of approximately two thirds of the
probes present on the chip (329561 out of 489318 total probes were
eliminated in DRG arrays; 339121 out of 489318 total probes were
eliminated in endoneurium arrays). As no chip replicate was
included in our experiment we decided to filter the probes
according to the coherence of their expression profiles. For this, we
selected probes up- or down- regulated more than 3 or 1.5-fold in
two or more consecutive time-points, with the additional
constraint that the expression level of the selected probes should
not vary over 1.5-fold outside these consecutive time-points
Figure 2. Characterization of motor and sensory behavior in Ins2Akita/+ mice. Sciatic nerve motor (MNCV, A) and tail sensory (SNCV, B) nerve
conduction velocities were compared in diabetic (Ins2Akita/+) and control (Ins2+/+) mice at two and five months of age. Results are expressed as the
mean 6 standard error of the mean (S.E.M). (Ins2+/+: n = 4; Ins2Akita/+: n = 4). C) Sensory performances were evaluated in two month old Ins2Akita/+ and
control littermates using the hot plate test at 49, 52 and 55uC. Results are expressed as the mean6standard error of the mean (S.E.M.) and analyzed
by Student’s t test (Ins2+/+: n = 8; Ins2Akita/+: n = 7). (*) p,0.05.
doi:10.1371/journal.pone.0010832.g002
Figure 3. Morphometric evaluation of peripheral nervous system of Ins2Akita/+ mice. A) Semi-thin toluidin blue stained cross sections of
sciatic nerves from three months old Ins2Akita/+ and control mice show well preserved nerve structures in both genotypes (scale bar: 15 mm). B) The
scatter plot displays g ratios (g ratio = axon area/axon+myelin area) of individual axons as a function of the respective axonal diameters determined
using sciatic nerves of three month old wild-type and Ins2Akita/+ mice. Each point corresponds to one fiber. Thin dark-grey and thick light-grey lines
represent the trend-lines for Ins2Akita/+ and wild-type mice respectively. The two lines are superimposed reflecting close similarity of the two data sets.
C) Axonal distribution represented as the percentage of axons for each class of sizes does not reveal any differences between wild-type and Ins2Akita/+
mice.
doi:10.1371/journal.pone.0010832.g003
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(Fig. S3). This strategy aimed at selecting the most robust gene
expression changes present through multiple time-points and
helped us to efficiently eliminate the ‘‘zigzagging’’ expression
profiles especially observed with genes expressed at low level (raw
expression ,100, see methods).
Using these filtering criteria, no probe showed a fold change
greater than 3 in at least two consecutive time-points in either
DRG or sciatic nerve endoneurium samples. Based on previously
published studies (Price et al., 2006), we decided to also use a less
stringent criterion of 1.5-fold change. In DRGs, 220 probes were
selected using this threshold as being differentially regulated in at
least 2 consecutive time-points (Table 1). However, the majority
of these probes (146 out of 220) had a low expression level. Out of
the 220 probes only 31 were up- or down-regulated in more than
two consecutive time-points. In sciatic nerve endoneurium, 331
probes met our filtering criteria as being differentially regulated in
at least two consecutive time-points (Table 1). As in DRG
samples, most of these probes (267 out of 331) had a low
expression level. Out of the 331 probes, 71 displayed a fold change
above 1.5 in more than two consecutive time-points.
The lowering of the fold change threshold to 1.5-fold had as a
consequence the decrease in the filtering stringency. In order to
assess the confidence of the filtering procedure, we have examined
some of the selected transcripts by quantitative PCR (qPCR, the
list of tested transcripts is provided in Table S1). For both tissues,
sets of probes differentially expressed in either 2, 3, 4, 5 or 6
consecutive time-points were selected. None of the 20 transcripts
selected based on the 1.5-fold change criteria and evaluated by
qPCR reproduced the expression pattern obtained with micro-
arrays. All qPCR reactions designed for these confirmations
resulted in PCR fragments of the expected size with good PCR
efficiency. In addition, the specificity of all primers was confirmed
by BLAST searching of the mouse genome database. Several
housekeeping genes were used as normalizers, however using
distinct normalizer genes did not affect the qPCR results. These
different controls exclude PCR reaction problems as an explana-
tion for the lack of reproducibility of our microarray results by
qPCR.
Our analysis therefore showed that some expression profiles
(mostly derived from genes with very low expression levels) pass
our filtering criterion of at least 1.5 fold change in two or more
consecutive time-points. However, the subsequent evaluation by
qPCR revealed that the majority if not all of these candidates are
false positives. Using more conservative filtering criteria (3 fold
change in two or more consecutive time-points) we were unable to
detect any transcriptional alterations in either endoneurial or
neuronal compartments of diabetic mice.
Effect of the onset of diabetes on the expression of
genes playing a role in DRG neuron development and
function
Since our expression profiling analysis did not reveal any global
transcriptional changes in either the endoneurium or the DRG of
diabetic mice, we decided to evaluate the expression of selected
genes previously shown to play an important role in development
or maintenance of these compartments.
In DRG, the expression of sodium channels (crucial for normal
propagation of action potentials) and of neurotrophic factors
Figure 4. Design of the microarray experiment. A) Eight time-points were selected between 20 and 56 days of age. This time window covers
the pre-symptomatic situation (P20, 20 days old), the onset of hyperglycemia (P24–P28), the onset of DPN (P32–P36) and later time-points with a
clear symptomatic situation (P36–P56) in Ins2Akita/+ mice. Squares: blood glucose; circles: MNCV. B) Schematic view of the microarray data analysis.
doi:10.1371/journal.pone.0010832.g004
Table 1. Number of probes differentially expressed between
Ins2Akita/+ and Ins2+/+ mice.
Tissue
# of consecutive
time-points
# of probes
observed
DRG 2 220 (12)
3 31 (11)
4 6 (5)
5 3 (2)
6 2 (1)
Sciatic nerve endoneurium 2 331 (8)
3 71 (8)
4 12 (5)
5 2 (2)
6 0
Only probes up- or down-regulated with a fold change of 1.5 in at least 2, 3, 4, 5
or 6 consecutive time-points and without any additional up- or down-
regulation exceeding the 1.5-fold threshold were selected by our filtering
criteria (see also Fig. S3). The number of genes tested by qPCR in each category
is presented in brackets.
doi:10.1371/journal.pone.0010832.t001
Transcriptional Changes in DPN
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(involved in neuronal survival) was already studied [31,32].
Recently, the developmental expression profiles of 17 sodium
channels and neurotrophin associated genes had been reviewed
[33]. These 17 genes were represented by 28 probes on the arrays
that we used. Eight genes were previously shown to be expressed
during early DRG development, but were absent in young adults
(Bdnf, Gdnf, Ngfa, Ngfb, Ngfg Ntf3, Nrtn and Scn3a [33]). The
expression of these genes was concordantly undetectable in our
DRG samples. Nine genes were described to be expressed at adult
stages with no major dynamic changes. Out of these 9 genes, six
(Ntrk1, Ret, Scn7a, Scn8a, Scna10a and Scn11a [33]) were detected in
our DRG samples (Fig. 5). None of these six genes met our less
stringent filtering criterion of 1.5-fold change in two or more
consecutive time-points, indicating that neither expression of
sodium channels nor that of neurotrophin associated genes were
affected by the onset of type 1 diabetes.
Effect of the onset of diabetes on the expression of
genes playing a role in Schwann cell myelination and
myelin maintenance
Even though we could not detect any major modifications in
myelin structure in Ins2Akita/+ PNS (Fig. 3A–C), subtle molecular
alteration in myelin gene expression could provide an early marker
of later stage irreversible pathological changes. We have therefore
analyzed the expression of genes encoding proteins involved in
myelin synthesis and/or maintenance in the sciatic nerve endoneu-
rium samples. Two transcription factors (Scip and Krox20)
regulating progression of myelination and myelin protein expression
respectively, together with the expression of four myelin proteins
(Pmp22, Mbp, Mag and Plp) were evaluated. No difference in
expressionwas observed between Ins2Akita/+ and Ins2+/+mice (Fig. 6).
Scip expression is known to peak during the onset of myelination (P2–
P4) and then to decrease with time [34]. In our profiling, the
decrease in the expression of this gene was accurately reproduced
(Fig. 6). In addition, Krox20, Pmp22, Mbp, Mag and Plp showed no
dynamic changes in adult stages, similar to previous studies [34]. The
expression of cholesterol metabolism related genes was previously
shown to closely match the expression of myelin genes [34]. None of
the cholesterol metabolism related genes tested in our experiment
met our filtering criterion of 1.5-fold change in two consecutive
conditions (for example see Cyp51, Dhcr7, Lss, Nsdhl, Sc4 mol, Sqle;
Fig. S4). Together these data indicate that the decreased NCV
observed in DPN is not the consequence of significant changes in
myelin gene expression that could potentially underlie structural
defects of myelin observed in more chronic stages of DPN.
Discussion
Phenotypic characterization of the development of DPN
in Ins2Akita/+ mice
In the present study, we performed a detailed characterization of
the onset of DPN in Ins2Akita/+ mice. The Ins2Akita/+ model provides
the advantage of studying hyperglycemia without the confounding
effect of toxic chemicals, such as streptozotocin, since Ins2Akita/+
animals spontaneously develop hyperglycemia at approximately
four weeks of age. Type 1 diabetes in the Ins2Akita/+ mice is a
consequence of an autosomal dominant mutation in the Ins2 gene
resulting in the improper folding of the Proinsulin 2 protein [26].
Transcription of the Ins2 gene is normally responsible for the
majority of the circulating insulin in the C57BL/6 wild-type mice. A
recent report suggested that the intracellular accumulation of the
misfolded Proinsulin 2 leads to progressive disruption of the insulin
secretory pathway organelle architecture and thereby resulting in
pancreatic b cell apoptosis [35].
Similarly to the previously described characterization of
Ins2Akita/+ mice [36] we found a progressive increase in blood
glucose level starting between three and four weeks of age.
Interestingly, our experimental design allowed us to detect the
presence of a DPN much earlier than previously reported [27]. We
observed a decrease in MNCV already one week after the onset of
hyperglycemia and a decrease in SNCV at P56, one month after
the onset of hyperglycemia, indicating that DPN affects both
Figure 5. Expression profiles of selected genes involved in sensory neuron development and function. Normalized levels of expression
at eight analyzed time-points (P20–P56) in both diabetic (Ins2Akita/+) and control (Ins2+/+) mice are shown. A) Ntrk1, B) Ret, C) Scn7a, D) Scn8a, E)
Scn10a, F) Scn11a. All values were normalized by the median of the intensity obtained for a probe throughout the chips.
doi:10.1371/journal.pone.0010832.g005
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motor and sensory nerve fibers. In contrast, Choeiri and
colleagues detected a decrease in SNCV in Ins2Akita/+ mice only
at four months of age. As the decrease in NCV of sensory fibers is
smaller than in motor fibers, the sensitivity of measurement could
be responsible for this discrepancy. A modest reduction in sensory
and motor function was also observed in six month-old diabetic
Ins2Akita/+ mice [37].
The observed deficit in MNCV and SNCV in Ins2Akita/+mice does
not seem to reflect a delay of PNS maturation since we could not
detect any differences in either myelin thickness or axonal size in three
month old affected animals and our microarray data does not reveal
any changes in the expression of genes involved in either Schwann cell
or neuronal maturation or function (see discussion below). This is in
line with results obtained from analysis of the onset of DPN in STZ-
induced type 1 diabetes at different developmental stages. If diabetes is
induced in older animals, deficits in MNCV and SNCV appear and
progress with a similar speed as compared to the induction of the
disease in younger animals ([38] and discussion within).
In the hot plate test, Ins2Akita/+ mice respond with increased
latency to heat compared to the control littermates. These results
are in line with the previously published evaluation of hind paw
analgesia in older Ins2Akita/+ mice, six months after the onset of
diabetes [37].
Overall, our phenotypic characterization of Ins2Akita/+ mice
suggests that these mice develop DPN rapidly after the onset of
diabetes and thus represent an interesting model of some of the
DPN symptoms observed in patients which often present
simultaneously positive (burning, neuropathic pain, abnormal
sensation to temperature) and negative (numbness, injury
insensitivity) sensory findings [4,29].
Transcriptional characterization of the development of
DPN in Ins2Akita/+ mice
We generated a time course of whole-genome expression data
covering the pre-symptomatic situation, the onset of hyperglyce-
mia, the onset of the DPN and finally the symptomatic period in
Ins2Akita/+ mice.
In sciatic nerve endoneurium samples, our gene expression
analysis of myelin and cholesterol genes showed a good
reproducibility with respect to previously published gene expres-
sion in wild-type mice [34]. Also, both myelin and cholesterol
metabolism gene expression was not affected in Ins2Akita/+ mice,
thereby confirming previously observed stability of myelin
structure even at a later developmental stage (48 weeks) in this
model [36]. In DRG samples, we reproduced the previously
described pattern of expression of sodium channels and neurotro-
phin associated genes [33]. The expression of these genes was not
affected by the onset of diabetes in Ins2Akita/+ mice. These results
are concordant with previous observations in STZ-injected rats.
Alterations of the expression of sodium channels Nav1.3, Nav1.6,
Nav1.8 and Nav1.9 [19] or modifications of DRG structure [39]
have been reported only in later stages of DPN.
The effect of diabetes on sympathetic neurons was previously
comprehensively analyzed in STZ-injected rats after two and six
weeks of diabetes [23]. Each of the two diabetes durations (2 and 6
weeks) was considered as a unique time-point. None of the 110
genes described as differentially expressed in para-vertebral or pre-
vertebral ganglia in STZ-injected rats was up- or down-regulated
with a fold change greater than 1.5 in two or more consecutive
time-points in our experiment. Global expression changes have
also been previously analyzed in STZ-injected rat DRG after one,
four and eight weeks of diabetes [24]. In this study the authors
chose a low threshold of 1.2 to maximize the number of
differentially expressed genes (from 800 to 1200 per time-point).
Similarly to our results, very small changes in gene expression were
observed in diabetic DRG compared to control littermates. Out of
the 113 published genes, none met our filtering criteria of 1.5-fold
change in two or more consecutive time-points. These discrepan-
cies are likely due to the fact that the onset of STZ-induced
diabetes is more rapid than the progressive destruction of b-cells
observed in Ins2Akita/+ mice. STZ-injected rodents reach a very
Figure 6. Expression profiles of selected genes involved in Schwann cell myelination. Normalized levels of expression at eight analyzed
time-points (P20–P56) are shown for control (Ins2+/+) mice. In diabetic (Ins2Akita/+) mice, the expression was analyzed only at 7 time-points (data point
P36 was excluded, see methods for more explanations). A) Scip, B) Krox20, C) Pmp22, D) Mbp, E) Mag, F) Plp. All values are normalized by the median
of the intensity obtained for a probe throughout the chips.
doi:10.1371/journal.pone.0010832.g006
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high level of glycemia within two days, whereas glycemia increases
progressively in Ins2Akita/+ mice.
DPN being a progressive disorder, we expected to find groups of
transcripts progressively up- or down-regulated as hyperglycemia
or DPN develops, with maximal changes in the later time-points.
However, there was no correlation between phenotypic changes
(onset of hyperglycemia and decreased MNCV) and transcrip-
tional modifications in Ins2Akita/+ mice. Using conservative filtering
criteria of 3-fold change in two or more consecutive time-points,
we were unable to detect any transcriptional alterations in either
endoneurial or neuronal compartments of diabetic mice. By
lowering the stringency criteria to 1.5-fold change in two or more
consecutive time-points, we detected some potentially differentially
expressed genes in either endoneurium or DRG of diabetic mice.
However, none of the 20 expression profiles selected based on 1.5-
fold change criteria could be confirmed by qPCR. These results
indicate that based on our experimental design, the 1.5- fold
threshold criterion is too low to reliably detect genes that are
differentially expressed over the time-course.
The observed gene expression stability in both the sciatic nerve
endoneurium and the DRG early after the onset of diabetes
suggest that the early (reversible) phase of DPN is not a
consequence of substantial transcriptional changes. We cannot
however exclude the existence of transcriptional changes present
only in a small fraction of cells in either the endoneurium or the
DRG. The sciatic nerve endoneurium is mainly composed of
Schwann cells, but also contains other cell types such as fibroblasts,
macrophages and blood vessels. It is considered that approxi-
mately 10% of the nuclei in the sciatic nerve endoneurium belong
to fibroblasts and another 2–9% to macrophages, while the
remainder are Schwann cell nuclei [40]. Similarly to the
endoneurium, DRG is composed of several populations of sensory
neurons and other cell types such as satellite and Schwann cells
[41,42]. Thus, if transcriptional changes induced by diabetic
conditions appear only in a specific cell population, these changes
may be obscured by the messenger RNAs of the other cell types
composing the tissues, which may prevent their detection by our
current approach. We are working on new strategies that will
allow us to efficiently purify mRNAs from selected endoneurial or
DRG cell populations to test this hypothesis.
Together our data suggest that global transcriptional programs
in both endoneurial and neuronal compartments of peripheral
nerves are relatively resistant to the onset of type 1 DPN. The
phenotypic changes observed during the onset of DPN, when the
disease phenotypes are still reversible, are most probably a
consequence of changes occurring at the post transcriptional level
[9] or due to small changes in gene expression level or changes in
restricted cell populations that are both below the level of
sensitivity of the screen presented in this study. Major transcrip-
tional changes may occur in the peripheral nervous system affected
by DPN, but in more chronic stages when irreversible structural
alterations appear.
Materials and Methods
Animals
All animals were housed in a controlled environment with a
12 h light/12 h dark cycle and free access to water and standard
laboratory diet (except for fasting animals which had access only to
water). Experiments were performed in accordance with the legal
requirements of the University of Lausanne and the Canton of
Vaud. C57BL/6J-Ins2Akita (Ins2Akita/+) mice were obtained from
The Jackson Laboratory (Bar Harbor, Maine, USA) and
genotyped according to a previously described protocol [26].
Measurement of blood glucose level
Tail vein blood glucose was determined with a glucometer
Ascencia Contour (Bayer).
Motor and sensory nerve conduction velocity (MNCV and
SNCV)
All animals were anesthetized with a mixture of 10 ml/g of
Ketanarkon 100 (1 mg/ml, Streuli) with 0,1% Rompun (Bayer) in
PBS. For MNCV, the left and right sciatic nerves were stimulated
at the sciatic notch and distally at the ankle via bipolar electrodes
with supramaximal square-wave pulses (5 V) of 0.05 milliseconds.
The latencies of the compound muscle action potentials were
recorded by a bipolar electrode inserted between digits 2 and 3 of
the hind paw and measured from the stimulus artifact to the onset
of the negative M-wave deflection. MNCV was calculated by
dividing the distance between the stimulating and recording
electrode by the subtraction of the distal latency from the proximal
latency. The sensory nerve action potential (SNAP) was recorded
at the tail and sciatic nerve. For the tail recordings, the caudal
nerve of the tail was stimulated distally and the bipolar electrode
was inserted proximally at the base of the tail. Latency of the
SNAPs was determined by measuring the stimulus artifact to the
onset of the S-wave deflection. The SNCV of the sciatic nerve was
recorded at the sciatic notch by stimulating the nerve with the
bipolar electrodes placed in the dorsal part of the hindpaw. SNCV
was calculated by dividing the distance between the stimulating
and recording electrode by the latency. Results were expressed as
the mean standard error of the mean (S.E.M.) and pair-wise
comparisons performed using the Student’s t-test.
Morphometric analysis
Mice were perfused with 1% PFA and 2% glutaraldehyde in
0.1 M cacodylate buffer (pH 7.3) for 5 min. Sciatic nerves were
dissected and post fixed by immersion in the fixative solution for
2 h at 4uC, washed in 0.1 M cacodylate buffer, and osmicated for
4 h in 1% OsO4 (Fluka). Nerves were rinsed in water, dehydrated,
and embedded in epon 812 resin (Fluka). One-micrometer sections
were stained with 1% toluidine blue and examined by light
microscopy. Subsequent morphometric analyses were performed
on micrographs using Image J plug-in (G ratio calculator)
developed in collaboration with the cellular imaging facility of
the University of Lausanne and available at http://cifweb.unil.ch.
Intraepidermal nerve fiber (IENF) density quantification
Footpads from 10 week old male Ins2Akita/+ and Ins2+/+ mice
were removed from the plantar area of the hind feet and fixed in
Zamboni’s fixative for 2 hours at room temperature. Tissues were
washed three times in PBS, kept in 30% sucrose/PBS overnight at
4uC and subsequently embedded in OCT medium (Sakura).
Frozen sections (50 mm) were prepared and six different sections
(using every fourth section) from each animal were immunostained
by a free-floating protocol. Sections were blocked in 0,3% Triton
X-100 followed by an incubation with the goat anti-Collagen IV
antibody (at a 1:40 dilution; Millipore) for 24 h at 4uC diluted in
blocking reagent. After three washes in PBS, samples were stained
with the secondary antibody anti-goat Alexa 594 (at a 1:200
dilution, Invitrogen) for 2 hours at room temperature. The
sections were then stained with the rabbit anti-PGP 9.5 (at a
1:400 dilution; Ultraclone) and anti-rabbit Alexa 488 antibody (at
a 1:200 dilution, Invitrogen). Finally, sections were transferred
onto a slide in a drop of PBS and, after drying, mounted with
Vectashield mounting medium containing DAPI to counterstain
cell nuclei (Vector Laboratories). Four fields per section and three
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sections per animal were quantified for IENF density. Images
based on the stack of consecutive 2 mm sections (usually 15
sections) were generated by using confocal microscopy (Leica SP5
AOBS Confocal Microscope). Single IENF crossing the basement
membrane between dermis and epidermis were counted, whereas
secondary branching and epidermal nerve fragments that do not
cross the basement membrane were excluded from the quantifi-
cation. The length of epidermis was measured using ImageJ and
the linear density of IENF (IENF/mm) was obtained. Counting
was carried out with the observer blinded to the origin (Ins2Akita/+
and Ins2+/+) of the image.
Sensory behavior assessment
All experiments were carried out by the same person, in the
same laboratory and in the same environment. Testing started
after habituation of the mice to the experimenter and to the
environment. The development of thermal hypersensitivity was
measured using a hot plate (Columbus Instruments). Mice were
placed on a hot plate set at 49u, 52u or 55uC. The nociceptive
behavior (paw licking or jumping from the hot plate) response
latency was recorded and animals were removed immediately
from the hotplate. Without response, animals were removed after
1 min, 45 or 20 seconds for the three temperatures respectively, to
diminish the potential of thermal injury. Three trials separated by
over ten minutes were averaged for each data point.
Total RNA preparation
Sciatic nerve endoneuriums and L5 DRGs were dissected from
P20, P24, P28, P32, P36, P40, P48 and P56 days old male
Ins2Akita/+ and Ins2+/+ mice. Since we have previously shown that
Schwann cells are sensitive to dietary changes [17], all animals
were subjected to 14 h fasting and to a subsequent 6 h refeeding
before sacrifice in order to limit the metabolic variation between
individuals. For each group, tissues from five mice were pooled
before RNA extraction. For each mouse, weight and blood glucose
were measured (Table S2) to build groups that contained minimal
phenotypic variation. In the set of animals used for microarray
experiments, increased glycemia was initially observed at P24 and
hyperglycemia became clear at P28, followed by a small decrease
in weight at P48 and P56. Total RNA from sciatic nerve
endoneuriums and DRGs was isolated using the Qiagen RNeasy
lipid tissue kit (Qiagen) following the manufacturer’s instructions.
RNA quality was verified by agarose gel and/or by 2100
Bioanalyzer (Agilent) and the concentration was determined by
the ND-1000 Spectrophotometer (NanoDrop).
cRNA synthesis
For each condition (pool of five mice), 300 ng of total RNA was
used to synthesize cRNA using the Illumina TotalPrep RNA
amplification kit (Ambion) following the manufacturer’s instruc-
tions. cRNA concentration was determined using a spectropho-
tometer, whereas cRNA quality was determined by 2100
Bioanalyzer (Agilent).
Illumina arrays
The MouseWG-6 v1 expression Beadchips (Illumina) were used
to determine differences in gene expression. Hybridizations were
carried out using the Illumina gene expression system according to
the manufacturer’s instructions. Briefly, biotin-labelled cRNA
(1.5 mg) was added to the array and incubated for 16–20 hours at
55uC. The bound biotin-labelled cRNA was then stained with
streptavidin-Cy3. After hybridization, the microarray chip was
washed, dried, and scanned by the Illumina BeadArray Reader.
The absolute intensity of each probe on the image was generated
with the BeadStudio software Version 1.5.1.3 (Illumina). Different
controls were performed to assess the quality of the hybridization.
The mean intensities of each chip, the mean intensities for
negative or positive controls and the mean intensities obtained for
random sequences (background level) were determined. All these
mean intensities were within normal ranges and were also
comparable among chips. Chips were also clustered based on
their similarities. All chips hybridized with DRG samples were
grouped within the same cluster. One of the chips hybridized with
a sciatic nerve endoneurium sample (P36 Ins2Akita/+) was clustered
within the group of DRG samples. This chip was therefore
eliminated from the analysis. BeadStation 5003 data were
extracted using the cubic spline normalization option of
BeadStudio Version 1.5.1.3 (Illumina). Each tissue was normalized
independently. Absent, marginal and present calls were defined
according to the mean intensity level of the probes (BeadStudio).
Data were then imported into GeneSpring V7.2 (Agilent
Technologies) for data visualization and filtering. Raw intensities
of present genes were ranging from 10 to 409000. Genes
represented by probes with a raw intensity under 100 (44% of
probes scored as present in DRG samples; 47% of probes scored
as present in sciatic nerve endoneurium samples) were therefore
considered as low expressors. The difference in expression level
between the 2 genotypes was calculated by dividing raw data
obtained for Ins2Akita/+ mice by raw data obtained for Ins2+/+ mice.
In this case, raw expression values less than 10 were converted to
10 (expression values ,10= ‘‘absent’’ calls). The array data is
accessible through the ArrayExpress database (accession number:
E-TABM-987; http://www.ebi.ac.uk/microarray-as/ae/).
Quantitative RT-PCR
250–500 ng of total RNA was subjected to reverse transcription
using the SuperScriptTM III First-Strand Synthesis System for RT-
PCR (Invitrogen) following the manufacturer’s instructions.
Resulting cDNA was used as a template for quantitative PCR
(qPCR). The cycling conditions were 95uC for 10 min, followed by
40 cycles of 95uC for 15 s, and 60uC for 1 min. To detect and
eliminate possible primer–dimer artifacts, a dissociation curve was
generated by adding a cycle of 95uC for 15 s, 60uC for 1 min and
95uC for 15 s. All primer sets produced amplicons of the expected
size and their specificity was also verified by BLAST searching of
the mouse genome database. Sample quantitation was performed
using a standard curve established from a serial dilution of a mix of
the samples. Results were normalized using the reference genes
cyclophilin or ubiquitin, which showed minimal changes in their
level of expression in the array data. See Table S1 for a complete
list of primers used for qPCR.
Supporting Information
Figure S1 Sciatic nerve SNCV measurements in three month
old control and Ins2Akita/+ mice. A tendency for reduced SNCV
was observed in diabetic (Ins2Akita/+) mice (p = 0.12). Results are
expressed as the mean 6 standard error of the mean (S.E.M).
(Ins2+/+: n = 4; Ins2Akita/+: n = 4).
Found at: doi:10.1371/journal.pone.0010832.s001 (0.15 MB TIF)
Figure S2 Intraepidermal nerve fiber density assessment in 10
week old control and Ins2Akita/+ mice. No difference was observed
between control and diabetic (Ins2Akita/+) mice. Results are
expressed as the mean6standard error of the mean (S.E.M).
(Ins2+/+: n = 3; Ins2Akita/+: n = 3).
Found at: doi:10.1371/journal.pone.0010832.s002 (0.15 MB TIF)
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Figure S3 Schematic description of the microarray filtering
criteria. Data are represented as a fold change between diabetic
(Ins2Akita/+) and control (Ins2+/+) mice. A fold change of one
represents an equal level of expression between Ins2Akita/+ and
Ins2+/+ mice. Values above or below one represent, respectively,
an increased or decreased level of expression in Ins2Akita/+ mice. A
cut-off of 1.5-fold change was used. In order for a probe to be
selected by our filtering, fold change should therefore be .1.5 or
,0.66 in 2, 3, 4, 5 or 6 consecutive time-points. In addition, we do
not allow the probe to vary in the level of expression for more than
1.5-fold outside these consecutive time-points. Two examples of
probes that would be selected using our criteria are shown: A)
expression profile with an up-regulation in 2 consecutive time-
points (black circles); B) expression profile with a down-regulation
in 3 consecutive time-points. Two examples of probes that would
be eliminated using our selection criteria are shown: C) expression
profile with an up-regulation in two consecutive time-points (P28–
P32), unchanged level of expression at P36–P40 and an up-
regulation at P48 would be eliminated by our filtering; D)
Expression profile with a down-regulation in 3 consecutive time-
points (P28–P36) followed by an up-regulation in an additional
time-point (P56) would also be eliminated by our filtering.
Found at: doi:10.1371/journal.pone.0010832.s003 (0.59 MB TIF)
Figure S4 Expression of selected cholesterol metabolism related
genes in sciatic nerve endoneurium samples. Normalized levels of
expression at eight analyzed time-points (P20–P56) are shown for
control (Ins2+/+) mice. In diabetic (Ins2Akita/+) mice the expression
was analyzed only at 7 time-points (data point P36 was excluded,
see methods for more explanations). A) Cyp51, B) Dhcr7, C) Lss,
D) Nsdhl, E) Sc4 mol, F) Sqle. All values are normalized by the
median of the intensity obtained for a probe throughout the chips.
Found at: doi:10.1371/journal.pone.0010832.s004 (0.72 MB TIF)
Table S1 List of primers used for qPCR confirmations.
Found at: doi:10.1371/journal.pone.0010832.s005 (2.73 MB TIF)
Table S2 Body weight and tail vein blood glucose measurements
in Ins2Akita/+ and control Ins2+/+ mice used for the microarray
experiment. Results represent the mean 6 standard error of the
mean (S.E.M.; Ins2+/+: n = 5; Ins2Akita/+: n = 5).
Found at: doi:10.1371/journal.pone.0010832.s006 (1.24 MB TIF)
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